Joint Position Paper on Pharmaceutical Excipient Testing and Control Strategies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Joint Position Paper on Pharmaceutical Excipient Testing and Control Strategies
This article presents collaborative positions among excipient manufacturers, drug product manufacturers, and members of the US Pharmacopeia on key issues pertaining to the control of pharmaceutical excipients stemming from a recent Pharmaceutical Quality Research Institute workshop.


Pharmaceutical Technology


The authors are members of the Pharmaceutical Quality Research Institute's Excipient Working Group. Brian Carlin is global manager of pharmaceutical research and development at FMC-Biopolymer (Princeton, NJ). Dale Carter is manager of product quality and management systems, Office of Compliance and Ethics, at Archer Daniels Midland Company (Decatur, IL). Moira Griffiths is director of quality operations at Pfizer (Groton, CT). Gregory Larner is statistics manager at Pfizer Scientific and Laboratory Services (Kalamazoo, MI). Kevin Moore, PhD, is a scientist, Excipients, at United States Pharmacopeia, (Rockville, MD). Barry Rothman is a senior compliance officer, at Center for Drug Evaluation and Research, US Food and Drug Administration (Rockville, MD). David Schoneker is chair of the International Pharmaceutical Excipients Council of the Americas, (IPEC-Americas) and director of global regulatory affairs at Colorcon (West Point, PA). Catherine Sheehan is director, Excipients and Food Chemical Codex at the United States Pharmacopeia. Rajendra Uppoor, RPh, PhD, is a pharmacist in the Office of Pharmaceutical Science, at Center for Drug Evaluation and Research, US Food and Drug Administration (Silver Spring, MD). Phyllis Walsh* is senior compendial manager at Schering-Plough Corporation (Kenilworth, NJ),
Robert Wiens* is senior quality representative at Eli Lilly and Company (Indianapolis, IN)

*To whom all correspondence should be addressed. The views expressed in this article are the authors' own and are not necessarily those of Archer Daniels Midland Company, Colorcon, Eli Lilly, FMC-Biopolymer, Pfizer, Schering-Plough, the US Food and Drug Administration, or the US Pharmacopeia.

Submitted: June 21, 2007. Accepted: July 18, 2007.

References

1. G. Larner et al., "PQRI Survey of Pharmaceutical Excipient Testing and Control Strategies Used by Excipient Manufacturers, Excipient Distributors, and Drug-Product Manufacturers," Pharm. Technol. 30 (9), 90–98 (2006).

2. 21 CFR Regulations can be accessed at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm (type Part and Section # in search, e.g. 211.84).

3. FDA, Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, http://www.fda.gov/cder/guidance/6419fnl.htm.

4. Federal Food, Drug, and Cosmetic Act, http://www.fda.gov/opacom/laws/fdcact/fdctoc.htm.

5. FDA, Guidance for Industry—Testing of Glycerin for Diethylene Glycol, http://www.fda.gov/cder/guidance/7654fnl.htm.

6. ICH Q6A, section 2.1, http://www.ich.org/cache/compo/276-254-1.html.

7. Good Trade and Distribution Practices for Pharmaceutical Starting Materials, World Health Organization, WHO Technical Report Series, No. 917, 2003.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here